BIBLIOGRAFÍA
Hay mas de 7.500 artículos científicos publicados y registrados en la biblioteca nacional de medicina de EEUU.
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN esti- mates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
2. Abiri B, Vafa M, Vitamin C, Cancer. The role of vitamin C in disease progression and quality of life in cancer patients. Nutr Cancer. 2021;73:1282–92.
3. Morrin HR, Pullar JM, Spencer E, Vissers MCM, Robinson BA, Dachs GU. Low vitamin C status in patients with cancer is associated with patient and tumor characteristics. Nutrients. 2020;12:2338. https://doi.org/10.3390/nu12082338.
4. Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci U S A. 2005;102:13604–9.
5. Chen Q, Espey MG, Sun AY, Lee JH, Krishna MC, Shacter E, et al. Ascorbate in pharmacologic concentrations selectively gen- erates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci U S A. 2007;104:8749–54.
6. Fu J, Wu Z, Liu J, Wu T, Vitamin C. A stem cell promoter in cancer metastasis and immunotherapy. Biomed Pharmacother. 2020;131:110588. https://doi.org/10.1016/j.biopha.2020.110588.
7. Mehdi WA, Zainulabdeen JA, Mehde AA. Investigation of the antioxidant status in multiple myeloma patients: effects of therapy. Asian Pac J Cancer Prev. 2013;14:3663–7.
8. Vollbracht C, Schneider B, Leendert V, Weiss G, Auerbach L, Beuth J. Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany. In Vivo. 2011;25:983–90.
9. Codini M. Why Vitamin C could be an excellent complementary remedy to conventional therapies for breast cancer. Int J Mol Sci. 2020;21:8397. https://doi.org/10.3390/ijms21218397.
10. Li P, Han B, Jia H, Mo S, Deng K, Huang Y, et al. High-dose vita- min C tends to kill colorectal cancer with high MALAT1 expres- sion. J Oncol. 2020; 2020:2621308. https://doi.org/10.1155/2020/ 2621308.
11. Zhang D, Xu P, Li Y, Wei B, Yang S, Zheng Y, et al. Association of vitamin C intake with breast cancer risk and mortality: a meta- analysis of observational studies. Aging. 2020;12:18415–35.
12. Roa FJ, Peña E, Gatica M, Escobar-Acuña K, Saavedra P, Mal- donado M, et al. Therapeutic use of vitamin C in cancer: physi- ological considerations. Front Pharmacol. 2020;11:211. https:// doi.org/10.3389/fphar.2020.00211.
13. Zasowska-Nowak A, Nowak PJ, Ciałkowska-Rysz A. High- dose vitamin C in advanced-stage cancer patients. Nutrients. 2021;13:735. https://doi.org/10.3390/nu13030735.
14. Moore C, Palau VE, Mahboob R, Lightner J, Stone W, Krishnan
15. K. Upregulation of pERK and c-JUN by γ-tocotrienol and not α-tocopherol are essential to the differential effect on apoptosis in prostate cancer cells. BMC Cancer. 2020;20:428. https://doi. org/10.1186/s12885-020-06947-6.
16. Figueroa Gonzalez D, Young F. Gamma tocopherol reduced chemotherapeutic-induced ROS in an ovarian granulosa cell line, but not in breast cancer cell lines in vitro. Antioxid (Basel). 2020;9:51. https://doi.org/10.3390/antiox9010051.
17. Wei CW, Yu YL, Chen YH, Hung YT, Yiang GT. Anticancer effects of methotrexate in combination with α–tocopherol and α–tocopherol succinate on triple–negative breast cancer. Oncol Rep. 2019;41:2060–6.
18. Ding Y, Fan J, Fan Z, Zhang K. γ-Tocotrienol reverses multi- drug resistance of breast cancer cells through the regulation of the γ-Tocotrienol-NF-κB-P-gp axis. J Steroid Biochem Mol Biol. 2021;209:105835. https://doi.org/10.1016/j.jsbmb.2021. 105835.
19. Peh HY, Tan WS, Liao W, Wong WS. Vitamin E therapy beyond cancer: tocopherol versus tocotrienol. Pharmacol Ther. 2016;162:152–69.
20. Harris HR, Orsini N, Wolk A. Vitamin C and survival among women with breast cancer: a meta-analysis. Eur J Cancer. 2014;50:1223–31.
21. Chen J, Jiang W, Shao L, Zhong D, Wu Y, Cai J. Association between intake of antioxidants and pancreatic cancer risk: a meta- analysis. Int J Food Sci Nutr. 2016;67:744–53.
22. Fritz H, Flower G, Weeks L, Cooley K, Callachan M, McGowan J, et al. Intravenous vitamin C and cancer: a systematic review. Integr Cancer Ther. 2014;13:280–300.
23. Nauman G, Gray JC, Parkinson R, Levine M, Paller CJ. System- atic review of intravenous ascorbate in cancer clinical trials. Anti- oxid (Basel). 2018;7:89. https://doi.org/10.3390/antiox7070089.
24. van Gorkom GNY, Lookermans EL, Van Elssen CHMJ, Bos GMJ. The Effect of Vitamin C (Ascorbic Acid) in the treatment of patients with cancer: a systematic review. Nutrients. 2019;11:977. https://doi.org/10.3390/nu11050977.
25. Jacobs C, Hutton B, Ng T, Shorr R, Clemons M. Is there a role for oral or intravenous ascorbate (vitamin C) in treating patients with cancer? a systematic review. Oncologist. 2015;20:210–23.
26. Alkhenizan A, Hafez K. The role of vitamin E in the prevention of cancer: a meta-analysis of randomized controlled trials. Ann Saudi Med. 2007;27:409–14.
27. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https://doi.org/10.1136/bmj.n71.
28. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of rand- omized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12. https://doi.org/10.1016/0197-2456(95)00134-4.
29. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. https://doi.org/ 10.1136/bmj.d5928.
30. Ou J, Zhu X, Chen P, Du Y, Lu Y, Peng X, et al. A randomized phase II trial of best supportive care with or without hyperthermia and vitamin C for heavily pretreated, advanced, refractory non- small-cell lung cancer. J Adv Res. 2020;24:175–82. https://doi. org/10.1016/j.jare.2020.03.004.
31. Allen BG, Bodeker KL, Smith MC, Monga V, Sandhu S, Hohl R, et al. First-in-human phase i clinical trial of pharmacologic ascorbate combined with radiation and temozolomide for newly diagnosed glioblastoma. Clin Cancer Res. 2019;25:6590–7.
32. Mikirova N, Casciari J, Hunninghake R. Continuous intravenous vitamin C in the cancer treatment: re-evaluation of a Phase I clinical study. FFHD. 2019;9:180–204.
33. Wang F, He MM, Wang ZX, Li S, Jin Y, Ren C, et al. Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOL- FIRI in patients with metastatic colorectal cancer or gastric cancer. BMC Cancer. 2019;19:460. https://doi.org/10.1186/ s12885-019-5696-z.
34. Zhao H, Zhu H, Huang J, Zhu Y, Hong M, Zhu H, et al. The synergy of Vitamin C with decitabine activates TET2 in leuke- mic cells and significantly improves overall survival in elderly patients with acute myeloid leukemia. Leuk Res. 2018;66:1–7.
35. Nielsen TK, Højgaard M, Andersen JT, Jørgensen NR, Zer- ahn B, Kristensen B, et al. Weekly ascorbic acid infusion in castration-resistant prostate cancer patients: a single-arm phase II trial. Transl Androl Urol. 2017;6:517–28.
36. Polireddy K, Dong R, Reed G, Yu J, Chen P, Williamson S, et al. High dose parenteral ascorbate inhibited pancreatic cancer growth and metastasis: mechanisms and a phase I/ IIa study. Sci Rep. 2017;7:17188. https://doi.org/10.1038/ s41598-017-17568-8.
37. Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Wagner BA, Cramer-Morales KL, Furqan M, et al. O2⋅- and H2O2-mediated disruption of Fe metabolism causes the differential susceptibility of NSCLC and GBM cancer cells to pharmacological ascorbate. Cancer Cell. 2017;31:487-500.e8.
38. Hoffer LJ, Robitaille L, Zakarian R, Melnychuk D, Kavan P, Agulnik J, et al. High-dose intravenous vitamin C combined with cytotoxic chemotherapy in patients with advanced cancer: a phase I-II clinical trial. PLoS One. 2015;10:e0120228. https://doi.org/ 10.1371/journal.pone.0120228.
39. Kawada H, Sawanobori M, Tsuma-Kaneko M, Wasada I, Miy- amoto M, Murayama H, et al. Phase I clinical trial of intravenous L-ascorbic acid following salvage chemotherapy for relapsed B-cell non-Hodgkin’s lymphoma. Tokai J Exp Clin Med. 2014;39:111–5.
40. Ma Y, Chapman J, Levine M, Polireddy K, Drisko J, Chen Q. High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med. 2014;6(222):222ra18. https://doi.org/10.1126/scitranslmed. 3007154.
41. Stephenson CM, Levin RD, Spector T, Lis CG. Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer. Cancer Chemother Pharmacol. 2013;72:139–46.
42. Welsh JL, Wagner BA, van’t Erve TJ, Zehr PS, Berg DJ, Halfda- narson TR, et al. Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chem- other Pharmacol. 2013;71:765–75.
43. Mikirova N, Casciari J, Rogers A, Taylor P. Effect of high-dose intravenous vitamin C on inflammation in cancer patients. J Transl Med. 2012;10:189. https://doi.org/10.1186/1479-5876-10-189.
44. Monti DA, Mitchell E, Bazzan AJ, Littman S, Zabrecky G, Yeo CJ, et al. Phase I evaluation of intravenous ascorbic acid in com- bination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One. 2012;7:e29794. https://doi.org/10. 1371/journal.pone.0029794.
45. Berenson JR, Yellin O, Woytowitz D, Flam MS, Cartmell A, Patel R, et al. Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen. Eur J Haematol. 2009;82(6):433–9. https://doi.org/10.1111/j.1600-0609.2009. 01244.x.
46. Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, Rosadiuk K, et al. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol. 2008;19:1969–74.
47. Yeom CH, Jung GC, Song KJ. Changes of terminal cancer patients’ health-related quality of life after high dose vitamin C administration. J Korean Med Sci. 2007;22:7–11.
48. Riordan HD, Casciari JJ, González MJ, Riordan NH, Miranda- Massari JR, Taylor P, et al. A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P R Health Sci J. 2005;24:269–76.
49. Correa P, Fontham ET, Bravo JC, Bravo LE, Ruiz B, Zarama G, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy. J Natl Cancer Inst. 2000;92:1881–8.
50. Moertel CG, Fleming TR, Creagan ET, Rubin J, O’Connell MJ, Ames MM. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemo- therapy. A randomized double-blind comparison. N Engl J Med. 1985;312:137–41.
51. Poulter JM, White WF, Dickerson JW. Ascorbic acid supplemen- tation and five year survival rates in women with early breast cancer. Acta Vitaminol Enzymol. 1984;6:175–82.
52. Murata A, Morishige F, Yamaguchi H. Prolongation of survival times of terminal cancer patients by administration of large doses of ascorbate. Int J Vitam Nutr Res Suppl. 1982;23:103–13.
53. Creagan ET, Moertel CG, O’Fallon JR, Schutt AJ, O’Connell MJ, Rubin J, et al. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. a controlled trial. N Engl J Med. 1979;301:687–90.
54. Cameron E, Pauling L. Supplemental ascorbate in the support- ive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A. 1978;75(9):4538–42. https://doi.org/10.1073/pnas.75.9.4538.
55. Thomsen CB, Andersen RF, Steffensen KD, Adimi P, Jakobsen A. Delta tocotrienol in recurrent ovarian cancer. A phase II trial. Pharmacol Res. 2019;141:392–6.
56. Springett GM, Husain K, Neuger A, Centeno B, Chen DT, Hutch- inson TZ, et al. A phase I safety, pharmacokinetic, and pharma- codynamic presurgical trial of vitamin E δ-tocotrienol in patients with pancreatic ductal neoplasia. EBioMedicine. 2015;2:1987–95.
57. Nesaretnam K, Selvaduray KR, Abdul Razak G, Veerasenan SD, Gomez PA. Effectiveness of tocotrienol-rich fraction combined with tamoxifen in the management of women with early breast cancer: a pilot clinical trial. Breast Cancer Res. 2010;12:R81. https://doi.org/10.1186/bcr2726.
58. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al. Effect of selenium and vitamin E on risk of pros- tate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009;301:39–51.
59. McKeown-Eyssen G, Holloway C, Jazmaji V, Bright-See E, Dion P, Bruce WR. A randomized trial of vitamins C and E in the prevention of recurrence of colorectal polyps. Cancer Res. 1988;48:4701–5.
60. Tabatabaei-Malazy O, Nikfar S, Larijani B, Abdollahi M. Influ- ence of ascorbic acid supplementation on type 2 diabetes mellitus in observational and randomized controlled trials; a systematic review with meta-analysis. J Pharm Pharm Sci. 2014;17:554–82.
61. Ghosn B, Benisi-Kohansal S, Ebrahimpour-Koujan S, Azadbakht L, Esmaillzadeh A. Association between healthy lifestyle score and breast cancer. Nutr J. 2020;19:4. https://doi.org/10.1186/ s12937-020-0520-9.
62. Zamani B, Daneshzad E, Azadbakht L. Dietary total antioxi- dant capacity and risk of gastrointestinal cancers: a systematic review and meta-analysis of observational studies. Arch Iran Med. 2019;22:328–35.
63. Khodaeian M, Tabatabaei-Malazy O, Qorbani M, Farzadfar F, Amini P, Larijani B. Effect of vitamins C and E on insulin resistance in diabetes: a meta-analysis study. Eur J Clin Invest. 2015;45:1161–74.
64. Vissers MCM, Das AB. Potential mechanisms of action for vitamin C in cancer: reviewing the evidence. Front Physiol. 2018;9:809. https://doi.org/10.3389/fphys.2018.00809.
65. Nagamma T, Baxi J, Singh PP. Status of oxidative stress and anti- oxidant levels in smokers with breast cancer from western Nepal. Asian Pac J Cancer Prev. 2014;15:9467–70.
66. Rouleau L, Antony AN, Bisetto S, Newberg A, Doria C, Levine M, et al. Synergistic effects of ascorbate and sorafenib in hepato- cellular carcinoma: New insights into ascorbate cytotoxicity. Free Radic Biol Med. 2016;95:308–22.
67. Yang Y, Lu X, Liu Q, Dai Y, Zhu X, Wen Y, et al. Palmitoyl ascor- bate and doxorubicin co-encapsulated liposome for synergistic anticancer therapy. Eur J Pharm Sci. 2017;105:219–29.
68. Parrow NL, Leshin JA, Levine M. Parenteral ascorbate as a cancer therapeutic: a reassessment based on pharmacokinetics. Antioxid Redox Signal. 2013;19:2141–56.
69. Cieslak JA, Strother RK, Rawal M, Du J, Doskey CM, Schroeder SR, et al. Manganoporphyrins and ascorbate enhance gemcit- abine cytotoxicity in pancreatic cancer. Free Radic Biol Med. 2015;83:227–37.
70. Xia J, Xu H, Zhang X, Allamargot C, Coleman KL, Nessler R, et al. Multiple myeloma tumor cells are selectively killed by phar- macologically-dosed ascorbic acid. EBioMedicine. 2017;18:41–9.
71. Espey MG, Chen P, Chalmers B, Drisko J, Sun AY, Levine M, et al. Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer. Free Radic Biol Med. 2011;50:1610–9.
72. Carr AC, Cook J. Intravenous vitamin C for cancer therapy- identifying the current gaps in our knowledge. Front Physiol. 2018;9:1182. https://doi.org/10.3389/fphys.2018.01182.
73. Du J, Cullen JJ, Buettner GR. Ascorbic acid: chemistry, biol- ogy and the treatment of cancer. Biochim Biophys Acta. 2012;1826:443–57.
74. Cui XY, Skretting G, Jing Y, Sun H, Sandset PM, Sun L. Hypoxia influences stem cell-like properties in multidrug resistant K562 leukemic cells. Blood Cells Mol Dis. 2013;51:177–84.
75. Jiang Q. Natural Forms of Vitamin E as Effective Agents for Can- cer Prevention and Therapy. Adv Nutr. 2017;8:850–67.
76. Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, et al. ML18147 Study Investigators. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14:29–37.
77. Gratz SW, Wallace RJ, El-Nezami HS. Recent perspectives on the relations between fecal mutagenicity, genotoxicity, and diet. Front Pharmacol. 2011;2:4. https://doi.org/10.3389/fphar.2011.00004.
78. Bonelli L, Puntoni M, Gatteschi B, Massa P, Missale G, Munizzi F, et al. Antioxidant supplement and long-term reduction of recur- rent adenomas of the large bowel. A double-blind randomized trial. J Gastroenterol. 2013;48:698–705.
